Howard W. Robin, President & CEO at NEKTAR THERAPEUTICS (NKTR), sold 20,000 shares at $59.97 ($1.2M) on 2026-06-16, disclosed to the SEC on 2026-06-18.
Scheduled sale ($1.2M) by President & CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $59.97 | 5,303 | $318K | 26.2% |
| 2 | $60.71 | 4,697 | $285K | 23.5% |
| 3 | $60.81 | 5,500 | $334K | 27.5% |
| 4 | $61.65 | 4,500 | $277K | 22.8% |
| Total | $60.75 avg | 20,000 | $1.2M | 100% |
| Filing → |
| NKTR | SELL | 2026-02-20 | $31K | — | Filing → |
| NKTR | SELL | 2025-11-25 | $240K | — | Filing → |
| NKTR | SELL | 2025-09-11 | $528K | — | Filing → |